Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACLX Arcellx	$66.25 +1.2%	$61.19	$47.86 ▼ $107.37	$3.65B	0.28	604,851 shs	435,469 shs
ALVO Alvotech	$10.50 -3.0%	$9.28	$7.35 ▼ $14.65	$3.17B	0.19	142,660 shs	368,008 shs
NAGE Niagen Bioscience	$11.51 -1.8%	$8.45	$2.31 ▼ $12.07	$906.64M	1.94	846,974 shs	632,420 shs
ZLAB Zai Lab	$36.54 +1.3%	$30.91	$16.01 ▼ $39.77	$4.03B	1.04	876,972 shs	890,054 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACLX Arcellx	+1.18%	+4.04%	+25.55%	-6.35%	+25.52%
ALVO Alvotech	-3.05%	-5.75%	+31.09%	-5.83%	-24.73%
NAGE Niagen Bioscience	-1.79%	+6.38%	+31.84%	+49.48%	+317.03%
ZLAB Zai Lab	+1.27%	+16.70%	+24.37%	+0.33%	+91.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACLX Arcellx	2.2844 of 5 stars	3.5	1.0	3.7	2.5	0.0
ALVO Alvotech	2.2523 of 5 stars	3.5	4.0	2.0	0.0	0.6
NAGE Niagen Bioscience	0.8497 of 5 stars	2.5	0.0	2.9	0.0	0.0
ZLAB Zai Lab	2.7143 of 5 stars	3.4	3.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACLX Arcellx	3.07	Buy	$111.33	68.05% Upside
ALVO Alvotech	3.00	Buy	$18.00	71.43% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.00	12.95% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	29.63% Upside

Current Analyst Ratings Breakdown

Latest NAGE, ACLX, ALVO, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/9/2025	ACLX Arcellx	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$133.00 ➝ $93.00
3/27/2025	ZLAB Zai Lab	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/13/2025	ZLAB Zai Lab	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$44.00 ➝ $51.00
3/7/2025	ZLAB Zai Lab	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$55.00

(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACLX Arcellx	$76.81M	47.53	N/A	N/A	$9.97 per share	6.64
ALVO Alvotech	$585.60M	5.41	N/A	N/A	N/A	∞
NAGE Niagen Bioscience	$107.93M	8.40	N/A	N/A	N/A	∞
ZLAB Zai Lab	$418.33M	9.64	N/A	N/A	$8.05 per share	4.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACLX Arcellx	-$70.69M	-$2.99	N/A	N/A	N/A	-25.94%	-8.28%	-5.21%	8/14/2025 (Estimated)
ALVO Alvotech	-$551.73M	$0.37	N/A	52.50	N/A	-123.47%	N/A	-35.87%	8/21/2025 (Estimated)
NAGE Niagen Bioscience	N/A	$0.17	67.71	∞	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	-$334.62M	-$2.49	N/A	N/A	N/A	-76.14%	-36.97%	-27.10%	8/5/2025 (Estimated)

Latest NAGE, ACLX, ALVO, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
3/26/2025	Q4 2024	ALVO Alvotech	-$0.74	-$0.24	+$0.50	-$0.24	$97.99 million	$153.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACLX Arcellx	N/A	4.29	4.29
ALVO Alvotech	N/A	2.69	1.92
NAGE Niagen Bioscience	N/A	N/A	N/A
ZLAB Zai Lab	N/A	3.01	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACLX Arcellx	96.03%
ALVO Alvotech	N/A
NAGE Niagen Bioscience	15.41%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ACLX Arcellx	8.35%
ALVO Alvotech	0.46%
NAGE Niagen Bioscience	9.39%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACLX Arcellx	80	55.11 million	50.70 million	Optionable
ALVO Alvotech	4	301.48 million	N/A	Not Optionable
NAGE Niagen Bioscience	120	78.77 million	N/A	N/A
ZLAB Zai Lab	1,950	110.33 million	94.24 million	Optionable

NAGE, ACLX, ALVO, and ZLAB Headlines

Recent News About These Companies

Yajing Chen Sells 9,618 Shares of Zai Lab Limited (NASDAQ:ZLAB) Stock

June 5 at 6:19 PM | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $288,540.00 in Stock

June 5 at 7:32 AM | insidertrades.com

Bank of America Corp DE Has $1.63 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

June 5 at 3:22 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's Why

June 4 at 10:52 AM | marketbeat.com

Squarepoint Ops LLC Acquires Shares of 27,961 Zai Lab Limited (NASDAQ:ZLAB)

June 3 at 3:57 AM | marketbeat.com

Legacy Wealth Asset Management LLC Buys Shares of 22,285 Zai Lab Limited (NASDAQ:ZLAB)

June 2, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) Short Interest Down 25.1% in May

June 2, 2025 | americanbankingnews.com

Millennium Management LLC Sells 15,023 Shares of Zai Lab Limited (NASDAQ:ZLAB)

June 1, 2025 | marketbeat.com

Zai Lab Limited (NASDAQ:ZLAB) Sees Large Drop in Short Interest

June 1, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial

May 31, 2025 | insidermonkey.com

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

May 31, 2025 | businesswire.com

Zai Lab Announces Participation in Investor Conferences in June 2025

May 30, 2025 | businesswire.com

Northern Trust Corp Increases Holdings in Zai Lab Limited (NASDAQ:ZLAB)

May 29, 2025 | marketbeat.com

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025 | seekingalpha.com

Zai Lab Limited Is Well Positioned For Long-Term Growth

May 28, 2025 | seekingalpha.com

BNP Paribas Financial Markets Purchases 18,472 Shares of Zai Lab Limited (NASDAQ:ZLAB)

May 26, 2025 | marketbeat.com

Twinbeech Capital LP Buys Shares of 27,039 Zai Lab Limited (NASDAQ:ZLAB)

May 24, 2025 | marketbeat.com

Zai Lab Limited: Banking On Chinese Pharma Growth

May 22, 2025 | seekingalpha.com

Woodline Partners LP Has $46.09 Million Stock Holdings in Zai Lab Limited (NASDAQ:ZLAB)

May 22, 2025 | marketbeat.com

Point72 Asset Management L.P. Purchases 270,136 Shares of Zai Lab Limited (NASDAQ:ZLAB)

May 22, 2025 | marketbeat.com

43,178 Shares in Zai Lab Limited (NASDAQ:ZLAB) Acquired by Lazard Asset Management LLC

May 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Palantir Scores First $1 Billion Contract; Is It Priced In?
By Chris Markoch | May 27, 2025
View Palantir Scores First $1 Billion Contract; Is It Priced In?
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
By Leo Miller | May 22, 2025
View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
By Leo Miller | May 22, 2025
View These 4 Top Investors Bought Over 6 Million Broadcom Shares in Q1
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
3 Alternative Asset Managers Are Raising Dividends by 5% to 25%
By Leo Miller | May 13, 2025
View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%

NAGE, ACLX, ALVO, and ZLAB Company Descriptions

Arcellx NASDAQ:ACLX

$66.25 +0.77 (+1.18%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$66.36 +0.11 (+0.17%)

As of 06/5/2025 07:36 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Alvotech NASDAQ:ALVO

$10.50 -0.33 (-3.05%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$10.49 -0.01 (-0.10%)

As of 06/5/2025 04:04 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Niagen Bioscience NASDAQ:NAGE

$11.51 -0.21 (-1.79%)

As of 06/5/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Zai Lab NASDAQ:ZLAB

$36.54 +0.46 (+1.27%)

Closing price 06/5/2025 04:00 PM Eastern

Extended Trading

$36.36 -0.18 (-0.49%)

As of 06/5/2025 06:24 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time